There is one clinical trial.
Characterization of fungal infections in COVID-19 infected and mechanically ventilated patients in ICU
Description: Prevalence of opportunistic fungal co-infections.Measure: Opportunistic fungal co-infections. Time: at 12 months
Description: Determination of the median time between entry in ICU and beginning of ARDS and (i) colonization and (ii) probable/proven infection with Aspergillus, Pneumocystis jirovecii and mucormycetesMeasure: Median time Time: at 12 months
Description: Evaluation of the time between diagnosis and targeted treatmentMeasure: Time between diagnosis and targeted treatment Time: at ICU discharge, up to 1 month
Description: Number of proposals for evaluation of preventive strategies if necessary, because of high incidence, in terms of chemoprophylaxis and/or environmental measuresMeasure: Preventive strategies Time: At 12 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports